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Abstract The validity for assigning disorder risk to an
autism spectrum disorder (ASD) candidate gene comes
from convergent genetic, clinical, and developmental
neurobiology data. Here, we review these lines of evidence
from multiple human genetic studies, and non-human
primate and mouse experiments that support the conclusion
that the MET receptor tyrosine kinase (RTK) functions to
influence synapse development in circuits relevant to
certain core behavioral domains of ASD. There is associ-
ation of both common functional alleles and rare copy
number variants that impact levels of MET expression in
the human cortex. The timing of Met expression is linked to
axon terminal outgrowth and synaptogenesis in the devel-
oping rodent and primate forebrain, and both in vitro and in
vivo studies implicate this RTK in dendritic branching,
spine maturation, and excitatory connectivity in the
neocortex. This impact can occur in a cell-nonautonomous
fashion, emphasizing the unique role that Met plays in
specific circuits relevant to ASD.
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Dysfunctional connectivity and autism spectrum
disorder
Virtually all neurodevelopmental disorders are defined by
deficits in brain circuitry and function that unfold as an
individual develops. Presumably, differential ontogeny of
neural connectivity—that is, when, how, and which specific
brain circuits are affected—dictates the presentation of
clinical phenotypes that characterize each neurodevelop-
mental disorder. While individuals with autism spectrum
disorder (ASD) often present with complex behavioral and
medical phenotypes (Geschwind 2009), connectivity-based
etiological hypotheses regarding the social and communi-
cation components of the diagnosis are supported by
numerous functional and structural imaging studies.
Functional magnetic resonance imaging (fMRI) studies
have demonstrated that distributed cortical areas are
activated less synchronously in individuals with ASD
during the performance of a variety of social and cognitive
tasks. These observations are consistent with long-range
functional connectivity in the cortex being broadly com-
promised in this disorder, although there is evidence that
connections with frontal and temporal cortices may be
especially vulnerable (see Geschwind and Levitt 2007 for
review). For example, during a sentence comprehension
task, there is less synchronous activation of distributed
language processing areas in ASD subjects (Just et al.
2004). However, compromised synchrony is selectively
observed in fronto-parietal areas during executive function
(Just et al. 2007) and social processing (Kana et al. 2009)
tasks. Tasks requiring face recognition (Koshino et al.
2008) or linguistic and visuospatial reasoning (Sahyoun et
al. 2010) also reveal reduced functional connectivity with
frontal cortical regions in individuals with ASD. In
contrast, occipito-parietal connectivity is intact (Koshino
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et al. 2008), or even enhanced (Sahyoun et al. 2010), when
performing these tasks. fMRI studies also have indicated
that interhemispheric connectivity is dysfunctional in ASD
(Pierce and Redcay 2008; Anderson et al. 2010).
Volumetric MRI and diffusion tensor imaging (DTI)
have provided anatomical evidence supporting the alter-
ations in functional long-range connectivity in ASD. For
example, brain-wide DTI analysis of the ASD brain reveals
reduced fractional anisotropy (FA) in most major long-
range fiber tracts, consistent with the view of some
investigators of a more global deficit in functional
connectivity (Shukla et al. 2010). The structural abnormal-
ities in the inferior fronto-occipital and superior longitudi-
nal fasciculi that have been reported in ASD (Shukla et al.
2010; Thomas et al. 2010) are especially relevant to deficits
in functional fronto-temporal and fronto-posterior connec-
tivity discussed above. Alterations in functional interhemi-
spheric connectivity have also been corroborated
anatomically by findings of altered white matter structure
within the corpus callosum (Shukla et al. 2010; Thomas et
al. 2010; Alexander et al. 2007). Moreover, these studies
provide evidence for heterogeneity in individual presenta-
tions of ASD. For example, Alexander et al. (2007) found
reduced FA in the corpus callosum in less than one-third of
their subjects with ASD, despite detecting an overall group
effect for the deficit. Similarly, reduced corpus callosum
volume is a variable anatomical phenotype in ASD. More
significantly, the magnitude of the reduction correlates with
the degree of dysfunctional connectivity and, possibly, the
severity of behavioral phenotypes (Just et al. 2007, but also
see Anderson et al. 2010). If similar structure–function
correlations manifest independently of each other across
multiple key cortical regions, this could, at least in part,
underlie the well-known heterogeneity in the severity of
core behavioral deficits in ASD.
In contrast to the functional hypoconnectivity of long-
range connections in ASD, it has been postulated that local
connectivity may be spared or hyperfunctional in ASD
(Geschwind and Levitt 2007; Casanova et al. 2002;
Courchesne and Pierce 2005; Levitt et al. 2004; Rubenstein
2010; Rubenstein and Merzenich 2003). This hypothesis
originally arose from observations in post-mortem tissue, in
particular the atypical minicolumn structure seen in several
regions of the cortex in brains from ASD individuals
(Casanova et al. 2002; Casanova et al. 2010). Unfortunate-
ly, current imaging techniques do not provide the structural
resolution to examine local cortico-cortical connectivity.
However, DTI does provide sufficient resolution to study
short-range association (i.e., U-association) fiber systems,
which, as recent studies indicate, are indeed compromised
in the frontal, parietal, and temporal lobes of subjects with
ASD (Sundaram et al. 2008; Shukla et al. 2011). In
addition, definitive evidence of altered local functional
connectivity in ASD is lacking, although this has not been
examined as rigorously as long-range connectivity. Inter-
estingly, recent fMRI studies have demonstrated that
increased local frontal lobe connectivity is associated with
an ASD risk allele that may predispose carriers to language
and implicit learning endophenotypes (Scott-Van Zeeland et
al. 2010).
ASD-associated genes: understanding the heterogeneity
of dysfunctional connectivity
Heritability and heterogeneity are two defining character-
istics of ASD. Strong genetic heritability in ASD is evident
from traditional twin studies, which have demonstrated
concordance values between 50% and 91% for monozy-
gotic twins and 0% for dizygotic twins (Folstein and Rutter
1977; Steffenburg et al. 1989). However, bivariate concor-
dance among individual traits of the ASD triad (e.g., social
impairment and communication impairment or social
impairment and restrictive and repetitive behaviors and
interests) has proven to be modest, indicating that distinct
groups of genes may influence each trait (Ronald et al.
2006a; b). This is consistent with heterogeneity in both the
severity of core deficits and the comorbidity of disorders
such as mental retardation and seizures in ASD (Geschwind
and Levitt 2007).
Behavioral heterogeneity in ASD is the readout of
connectivity of brain circuits; given the clinical complexity
of individuals with the disorder, many circuits must be
involved, perhaps to different degrees in each individual. In
turn, the dysfunctional connectivities that underlie hetero-
geneous ASD subtypes are presumably owed to develop-
mental interactions among a variety of possible ASD risk
genes and environmental influences. Risk genes may
selectively confer vulnerability to developing circuitry that
relates to a specific ASD core deficit. Alternatively, through
epistatic relationships, risk genes may interact to disrupt
expression patterns and/or levels of proteins that function in
specific signaling pathways that globally impact ASD-
relevant circuitry. In either case, heterogeneity results not
only from the particular combination of risk genes
expressed, but also from their pleiotropic functions in
various other pathways (Bill and Geschwind 2009). In
addition, while not particularly well-understood, we spec-
ulate that disorder heterogeneity also could be impacted by
co-occurrence of exacerbating environmental factors that
might otherwise more broadly impact connectivity. Even
further, heterogeneity can occur as a function of the timing
of the genetic insult. Here, two risk genes may specifically
impact circuits related to social interaction but do so during
distinct developmental epochs. If the expression of one
gene is related to cell migration and expression of the other
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is related to a later process, such as synaptogenesis, the
qualitative nature of their impact on that circuitry may be
quite different. For example, during hippocampal develop-
ment, disruption of Disc1 function alters the migration of
granule neurons (Meyer and Morris 2009) and it has been
suggested that this would subsequently affect the integra-
tion of these neurons into hippocampal circuitry. In
contrast, disruption of TrkB signaling in these same
neurons has no effect on the migration of granule neurons,
but alters their maturation such that there is a reduction in
the number of synaptic contacts, as well as synaptic
vesicles, made by these cells (Otal et al. 2005). Considering
the immense complexity of genetic and environmental
interactions over development, significant progress in
understanding the etiology of ASD will likely occur with
the characterization of ASD risk alleles, individually, in the
context of understanding their role in mediating histogenic
events that ultimately impact circuit development.
Rare mutations in genes such as NLGN3, NLGN4,
NRXN1, NRXN3, and SHANK3 are enriched in ASD
compared to the general population, and are intriguing
because of their clearly established roles in synaptogenesis
and the maintenance of synaptic connectivity (Varoqueaux
et al. 2006; Tabuchi et al. 2007; Hung et al. 2008; Gibson et
al. 2009). However, to date, expression studies of these
genes (Varoqueaux et al. 2006; Lim et al. 1999) have not
provided the resolution required to understand their
potential relationship to the development of forebrain
circuits affected in ASD. Further confusing the issue is
the fact that, in some cases, these gene mutations have been
associated with both mental retardation and ASD in the
same family (Laumonnier et al. 2004). Moreover, these
ASD-enriched mutations are exceedingly rare, suggesting
that their contribution to ASD, which affects 1 in 110
children, at a population level is minimal. In contrast, an
example of a strong link between an ASD risk allele and
potential etiological mechanisms has come from studies of
the PTEN locus. In 2005, Butler and colleagues found an
enrichment of rare loss-of-function mutations in the PTEN
gene within a subset of individuals with ASD and comorbid
macrocephaly (Butler et al. 2005). Remarkably, subsequent
studies in a mouse model of postnatal, forebrain-specific
PTEN loss-of-function revealed ethologically relevant
deficits in social behavior, as well as macrocephaly that
were due to increased dendritic and axonal arborization
(Kwon et al. 2006). Excitement concerning this finding,
however, is tempered by the fact that germ-line PTEN
mutations are rare (<1 in 10,000) and relevant to only a few
ASD cases. Insight into etiological mechanisms that are
more broadly relevant to idiopathic cases of ASD may
come from studies of common ASD risk alleles, though this
has its own challenges because of effect sizes that typically
are small (Nestler and Hyman 2010). In a few recent
examples, common and rare copy number variants of the
same genes that are enriched in ASD have emerged,
including contactin-associated protein-like 2 (Alarcon et
al. 2008; Bakkaloglu et al. 2008) and the MET receptor
tyrosine kinase. With respect to the MET gene, multiple
laboratories have established variants in the promoter
region, as well as rare copy number variations, as risk
alleles for ASD. Moreover, converging data from both
human and animal studies are providing insights into the
biological consequences of disrupted MET signaling, both
in the brain and peripheral organs. Thus, beyond the
statistical correlations, neurobiological studies are provid-
ing testable hypotheses for links between disrupted MET
gene expression and specific endophenotypes.
The emergence of the Met receptor tyrosine kinase
as an ASD risk gene
Over the past 5 years, five independent studies, using non-
overlapping family and case–control cohorts, have demon-
strated the association of three allelic variants of the gene
encoding the MET receptor tyrosine kinase (MET) with
ASD (Campbell et al. 2008; Campbell et al. 2006; Sousa et
al. 2009; Jackson et al. 2009; Thanseem et al. 2010). The
variants are all located in the putative 5′ regulatory region
and have been associated with increased risk (Fig. 1). It is
important to emphasize that genetic risk for any disorder,
including ASD, requires translation into an altered biology.
At least one MET variant, the rs1858830 ‘C’ allele, results
in altered biological function, as shown in gel shift and
transcriptional assays (Campbell et al. 2006). Specifically,
the ‘C’ allele results in reduced transcriptional efficiency in
vitro, a finding that is consistent with the twofold decrease
in temporal neocortical MET protein expression observed
in ASD post-mortem cases (Campbell et al. 2007).
Furthermore, the ‘C’ allele, independent of diagnosis,
correlates with levels of MET expression. With a calculated
relative risk of 2.29 for ASD, the combined data strongly
support the conclusion that the rs1858830 ‘C’ allele is
functional, yielding reduced expression of a protein that
impacts circuit development and function (see below).
Additional genetic studies indicate that MET and other
genes encoding proteins in the MET receptor signaling
pathway serve as risk factors for ASD. First, two studies
report rare copy number variants that interrupt the MET
gene preferentially in ASD but not in control populations
(Marshall et al. 2008; Pinto et al. 2010). Second, mutations
in genes that cause rare syndromes or macrocephaly,
including tuberous sclerosis, neurofibromatosis, and PTEN,
have high co-diagnosis of ASD. These genes encode
proteins that are critical for MET receptor signaling (Levitt
and Campbell 2009). Third, there is an enrichment of the
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rs1858830 risk variant in a stratified subpopulation of
children with ASD that is characterized by co-occurring
gastrointestinal (GI) disorders (Campbell et al. 2009a),
which are over abundantly represented in ASD (Campbell
et al. 2009a; Buie et al. 2010; Ibrahim et al. 2009). The
analysis of MET variation in ASD-GI comorbid disorders
was prompted by reports that MET positively regulates the
development and repair of gut epithelial cells (Kitamura et
al. 2000; Matsubara et al. 1998; Tahara et al. 2003).
Moreover, the enrichment speaks to the relevance of
connecting allelic variation to specific pathophysiological
processes. Yet, despite this preponderance of convergent
genetic evidence, general acceptance of MET as an ASD
risk gene, based on common variation and rare copy
number variations (CNVs), will be gained only insofar as
its developmental neurobiological functions can be related
specifically to ASD pathogenesis.
Met functions in neural development
The MET receptor was first identified as a proto-oncogene
(Cooper et al. 1984), and the context in which MET function
is best understood is in cancer biology (Trusolino et al. 2010).
Thus, the recognition of MET serving as a key signaling
component in specific neurodevelopmental events is relative-
ly new. MET signaling commences upon the binding of its
polypeptide ligand, hepatocyte growth factor (HGF). HGF
binding induces MET receptor oligomerization and the
autophosphorylation of intracellular tyrosine residues that
serve as multi-substrate docking sites for signaling adaptor
proteins (Trusolino et al. 2010; Ponzetto et al. 1994). These
adaptor proteins in turn facilitate the activation of several
major signaling cascades including the PI3K, ERK, and p38
systems (Trusolino et al. 2010; Stefan et al. 2001). Like other
members of the receptor tyrosine kinase family, the nature of
MET signaling is context- and cell-type-dependent, reflecting
pleiotropic roles in cellular development.
Met signaling in cells grown in vitro has been shown to
potentiate virtually every aspect of development involved in
establishing neural connections. Several in vitro models
have been used to show that Met activation regulates
dendritic outgrowth of neocortical and hippocampal pyra-
midal neurons (Gutierrez et al. 2004; Lim and Walikonis
2008). Axon outgrowth can be potentiated by Met
signaling, as shown in dissociated and explant culture
systems (David et al. 2008; Powell et al. 2003). Further
in vitro studies demonstrate that Met influences the
formation, molecular differentiation and function (Akimoto
et al. 2004; Tyndall et al. 2007; Tyndall and Walikonis
2006; 2007) of synaptic connections between forebrain
neurons. With the exception of the putative role for Met in
motor axon outgrowth (Ebens et al. 1996), however, these
findings have yet to be extended to in vivo contexts.
Moreover, because Met expression is readily modified by
environment, one must be cautious in assuming that Met
signaling functions defined in vitro will necessarily reflect
in vivo physiology. For example, HGF-mediated activation
of Met enhances the motility of cells derived from the fetal
ganglionic eminence (Powell et al. 2001), which go on to
form neocortical interneurons. Yet, recent studies from our
laboratory demonstrate that fetal ganglionic eminence cells
and neocortical interneurons do not express transcript or
protein in vivo and, thus, genetic deletion of Met in vivo
fails to alter cortical interneuron development (Judson et al.
2009; Eagleson et al. 2010). The apparent contradictory in
vivo and in vitro data were reconciled by the demonstration
that Met protein expression is induced in fetal ganglionic
eminence neurons in culture (Eagleson et al. 2010). Thus,
as with other ASD risk genes, connecting experimental data
to neurodevelopmental perturbations that are relevant to
ASD is challenging.
Fig. 1 Diagram illustrating the
three allelic variants of the gene
encoding the MET receptor ty-
rosine kinase (MET) that have
been associated with an in-
creased risk for ASD in multiple
independent studies. In addition,
rare copy number variants
(CNVs) that interrupt the MET
gene have been associated with
ASD. See reference list for
citations noted in the figure
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Met—a new player at the developing synapse
Recent transcript and protein mapping studies in the
developing mouse forebrain have provided a clearer picture
of cell-type specific and spatio-temporal features of Met
expression (Judson et al. 2009; Eagleson et al. 2010), and
have helped to identify testable, putative neurodevelop-
mental roles for the receptor in vivo. First, it was found that
Met mRNA exhibits limited expression in the mouse
forebrain (defined as pallial- and subpallial-derived cortical
and subcortical structures) prenatally, with detectable
transcript in the neocortical plate, hippocampus, amygdala,
and septum by embryonic day (E) 17.5. Expression
increases dramatically postnatally in these same regions,
coinciding temporally with the rapid growth of neuropil
elements that form synapses. In the mouse, the rapid phase
of synaptogenesis extends over a 2-week period [postnatal
days (P) 7–21], followed by pruning that extends through
the third and fourth week. Met expression in the forebrain
corresponds to phases of rapid axon terminal growth and
early synaptogenesis, as shown by increases through P7,
followed by a steady decline through the next week, and
then a rapid and robust decrease in transcript by puberty.
Importantly, Met transcript in the neocortex co-localizes
with markers of excitatory projection neurons during
development (Eagleson et al. 2010), but not inhibitory
neurons, astrocytes, or oligodendrocytes.
Transcript mapping reveals origins of protein translation,
but immunocytochemistry reveals sites of protein localiza-
tion and, perhaps, functional activity (Fig. 2). Analysis of
anti-Met immunolocalization reveals a temporal pattern of
protein expression that is identical to that found for Met
mRNA. Spatially, however, there are substantive differ-
ences. Whereas the neocortex, amygdala, hippocampus,
and septum all express Met protein (as well as transcript),
additional forebrain areas that do not express the Met
transcript are immunopositive. In particular, the striatum
and dorsal thalamus, two major targets of corticofugal
projections, express Met protein during the P0–14 period of
intensive terminal axon growth and neuropil development.
Importantly, a dorsal pallial promoter-driven functional
deletion of Met eliminates immunostaining from all but a
few structures in the forebrain (Judson et al. 2009). Thus,
Met expression in the striatum and dorsal thalamus
originates from excitatory projection neurons in the
neocortex, with the protein transported in developing axons
during axonal growth and synapse formation. In fact,
intense immunolocalization of Met is observed in the
internal capsule, fornix, corpus callosum, and anterior
commissure, all of which carry axons from the neocortex
to other cortical and subcortical destinations. Whereas the
localization in subcortical structures that receive cortical
input is clearly presynaptic, the subcellular distribution of
Met in the neocortex proper may be both pre- and
postsynaptic. This awaits ultrastructural validation in vivo.
Descriptive mapping data from the developing mouse
forebrain demonstrate a spatio-temporal pattern of gene and
protein expression that is consistent with a role in
development. What specific histogenic events then are
perturbed due to the elimination of Met signaling? Laminar
and cytoarchitectural organization of the neocortex and
subcortical regions that express the Met transcript are
normal. Detailed morphometric studies of post-pubertal,
kinase-dead, conditional Met mutant mice indicate alter-
ations in neocortical pyramidal neuron dendritic morphol-
ogy (Fig. 3; Judson et al. 2010). In these conditional Met
Fig. 2 Summary of MET/Met
expression in the developing
primate and mouse forebrain.
Green shading indicates
immunolocalization of the
receptor protein in cortical and
Subcortical regions and axon
tracts. Regions denoted do not
express the Met transcript (based
on analyses in the mouse), but
have detectable protein because
each structure receives Met-
immunoreactive axons. See
(Judson et al. 2009; Judson et al.
2011) for more details
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mutant mice, there are differential, compartment-specific
changes in layer 2/3 pyramidal cell dendritic branching.
Specifically, increases in branching in the basal dendrites
are offset by accompanying reductions in branching in
apical dendrites to the apical arbor. Consequently, overall
dendritic length in this neuron population is unchanged
relative to wild-type controls. However, because distal
dendritic length is preferentially lost, the cortical volume
coverage of the dendritic tree is, on average, significantly
reduced. These compartment-specific changes are sugges-
tive of presynaptic consequences of Met signaling dysfunc-
tion that are driven by distinct afferent inputs to the
pyramidal cell dendritic arbor. A potential presynaptic
mechanism of Met signaling dysfunction is strongly
supported by the observation that dendritic branching is
also altered in medium spiny neurons (MSN) in conditional
Met mutant mice. Notably, unlike cortical pyramidal
neurons, MSNs themselves do not express Met during
development, but receive heavily Met-expressing cortico-
striatal afferents.
Our investigation of the conditional Met mutant mice
revealed abnormal dendritic spine morphology. Spine
volume on basal dendrites is increased by approximately
22%, without changes in spine numbers. Changes of this
magnitude, while seemingly modest, have been shown to
translate into a linear enhancement of Ca++ influx, which on
a per spine basis would increase excitatory synaptic
transmission (Matsuzaki et al. 2001), consistent with our
recent electrophysiological data (see below). Analysis of
MSN spine morphology also reveals an increase in spine
volume. Because the analysis was done in post-pubertal
animals, these changes are likely to be permanent.
How do these alterations in dendritic and spine mor-
phology compare to studies examining the impact of single
gene alterations for syndromic neurodevelopmental disor-
ders? Table 1 summarizes numerous studies in mice for
genes implicated in syndromic disorders for which an ASD
diagnosis is common. The extent of reported dendritic and
spine alterations are generally comparable to those that
occur when Met is deleted functionally in conditional Met
mutant mice. Of particular interest is that many of the
syndromic disorders involve genes that encode proteins in
the same intracellular signaling pathways (ERK/PI3 Ki-
nase) through which Met and other receptor tyrosine
kinases signal. It is unclear, however, how ubiquitously
expressed signaling pathways can differentially impact
specific circuits, but one possibility is that phenotypic
heterogeneity may in part be owed to diverse upstream
signaling disruptions that converge on these conserved
downstream pathways (Bill and Geschwind 2009; Levitt
and Campbell 2009). The functional implications of
different syndromic disorder mutations examined in mice
are varied. Different behavioral tasks have been used to
detect pronounced cognitive impairments, altered social
behavior and physiological changes that reflect altered
synaptic function (Lee and Silva 2009; Crawley 2008).
Our recent efforts have focused on providing a physio-
logical translation of the structural changes that manifest
when Met is conditionally deleted from cortical excitatory
neurons. Using a combination of local circuit electrophys-
iological mapping by laser scanning photostimulation and
paired recordings, we revealed that local excitatory con-
nections from cortical layer 2–3 pyramidal neurons onto
specific subpopulations of layer 5 pyramidal neurons are
Fig. 3 Conditional Met deletion
by Emx1Cre (−/−) increases
proximal and reduces distal api-
cal dendritic branching of
neocortical pyramidal neurons
in post-pubertal animals. The
overall impact results in a re-
duced volume of cortical tissue
sampled by the apical dendrites.
Analysis of spine number and
size on basal dendrites revealed
an approximately 22% increase
in spine head volume, but no
change in density of spines. See
(Judson et al. 2010) for details
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enhanced twofold (Qiu et al. 2011). Moreover, layer 5
neurons that do not express Met failed to exhibit this
enhanced local circuit input. These experimental data are
consistent with human imaging evidence suggesting that
subsets of local cortical connections in ASD may be
atypically enhanced (Scott-Van Zeeland et al. 2010). We
also have preliminary data showing reduced sustainability
of long-term potentiation and poorer cognitive performance
in behavioral tasks. As these studies emerge, the relevance
of Met signaling in the establishment of proper circuit
function will become more evident.
MET in ASD risk—clinical and animal studies converge
The original study of MET in two large family cohorts with
ASD subjects, with a calculated relative risk of approxi-
mately 2.3, suggests that the functional ‘C’ promoter allele
generates modest risk for non-syndromic, idiopathic ASD.
This initial conclusion is supported by subsequent replica-
tion in additional family and case–control studies, the
association of two other promoter alleles that yield smaller
risk effects and CNVs (see above). Yet ASD is decidedly
heterogeneous, suggesting that no single gene will increase
risk for all subjects diagnosed with the disorder. In our
initial analyses of more than 700 families, the MET
functional allele was overrepresented in those subjects
identified as being part of multi-incident families (more
than one child with ASD), but not single-incident families
(Campbell et al. 2006). This is consistent with the idea that
common genetic predisposing factors for complex poly-
genic disorders, such as the ‘C’ MET promoter allele for
ASD, are more likely to be enriched in multi-incident
families (Risch 2001). These data indicate that further
stratification of populations may yield additional insight
regarding the role of MET in ASD risk.
Most children with neurodevelopmental disorders exhib-
it a variety of medical and psychiatric conditions (Batshaw
2002; Reber 2002), and this indeed occurs in ASD
(Geschwind 2009). This likely reflects the pleiotropic
nature of many of the proteins encoded by genes that
increase ASD risk. A recent study from our laboratory
indicates that analysis of genetic risk across functional
groupings in large cohorts may provide insight into
biological influences that yield such clinical heterogeneity.
Specifically, we find that in families in which a child is
Table 1 Summary of in vivo analyses of morphological changes in mice carrying mutations of ASD-related syndromic disorders compared to
Met deletion
Syndrome/gene Gene mutation Developmental
time of analyses
Morphological changes on neocortical
pyramidal neurons
References
Met Receptor Metfx/fx/Emx1Cre Post-pubertal
(P40)
∼22% ↑ in ↓ spine volume; 20% in
total dendritic tree volume; no change
in total dendrite length
(Judson et al. 2010. JCN)
Fragile X Fmr-1 null Adult No changes in dendrites/spines (Galvez and Greenough 2005;
Nimchinsky et al. 2001)
Fmr-1 null P7 ∼15–30% ↑ in immature spine #s;
20–28%
↑ in spine length
(Nimchinsky et al. 2001;
Comery et al. 1997;
Irwin et al. 2002)
Neurofibromatosis-1 NF-1 null None None None
AngelmanSydnrome Maternal
Ube3a null
Adult 30% ↓ in spine density; 10% ↓ in
spine length




25% ↓ in spine density on basal
dendrites in layer 2/3




15% ↓ in spine density on layer 5
basal dendrites but no change in
apical density; no change in
dendritic branching
(Sato and Stryker 2010)
Rett Syndrome Mecp2 A140V
knock-in
Adult Segment-restricted 50% ↓ in dendritic
branching
(Jentarra et al. 2010)
Mecp2 Hemizygous Adult 25% ↓ in spine number; 40% in dendrite
diameter
(Fukuda et al. 2005)
Mecp2 Hemizygous Adult 20-40% ↓ in dendritic branching; no difference
in spine number
(Kishi and Macklis 2010)
Tuberous Sclerosis Tsc1 null P20 15% ↑ in spine head width; 20% ↑ in
spine length; 25% ↓ in spine density
(Tavazoie et al. 2005)
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diagnosed with ASD and has a reported gastrointestinal
condition, the MET functional ‘C’ allele is even further
enriched when compared to children with ASD alone
(Campbell et al. 2009a; b). Why is there a connection?
MET is expressed in the developing gut in humans
(Kermorgant et al. 1997) and mice (Gorrindo et al.
unpublished data). In addition, HGF-Met signaling in
experimental models of colitis improves epithelial repair
(Tahara et al. 2003). Thus, it would be predicted, based on
animal studies, that alterations in Met signaling would
influence circuit formation in the brain, as well as gut
function. Our findings of subgroup enrichment of the
functional MET risk allele are consistent with this predic-
tion and provide insight into how genetic risk may translate
into biological influences that yield relevant clinical
phenotypes.
There have been significant challenges in identifying
how specific risk genes may impact the core social and
communication functions that are used diagnostically to
identify children with ASD. Expression databases and
mapping in mice (e.g., Allen Institute for Brain Science,
http://www.brain-map.org/) indicate that many rodent
orthologues of ASD risk genes, particularly those that carry
rare mutations, can be expressed relatively broadly in the
brain, and when mutated, result in significant cognitive
impairments in mice (in addition to disruption of social and
emotional regulation). These impairments are analogous to
the generalized intellectual disability that occurs in children
with ASD and those with syndromic disorders in which
ASD is often co-diagnosed. Yet in instances in which the
primate orthologous genes/proteins are mapped, there may
be noted species differences in expression. For example,
expression of CNTNAP2 is enriched at mid-gestation in
frontal lobe regions of the human (Alarcon et al. 2008), but
is ubiquitous in the mouse brain. To gain insight into
potential species-specific patterns of MET/Met expression,
we recently compared immunohistochemical staining pat-
terns of orthologous receptors in the rhesus monkey (MET)
and mouse (Met; Judson et al. 2011). We focused on late
pre- and early postnatal periods of development (Fig. 2),
when axonal terminal growth and synaptogenesis progress
rapidly (Bourgeois 1997). The temporal expression of
MET/Met in relation to axonal targeting and early phases
of synapse formation is highly conserved between species,
peaking near P7 in the mouse and around gestational day
150 in the monkey (Judson et al. 2011). Moreover,
subcortical forebrain expression is similar, with immunos-
taining evident in the neuropil of many of the same
amygdala subnuclei, the subiculum and CA1 of the
hippocampal formation, and the medial mammillary nuclei,
among other structures. Expression of MET/Met in growing
axons is highly conserved across species, but in patterns
within fiber tracts that reflect major differences in cortical
distributions. Whereas there is widespread expression
throughout the mouse neocortex, MET protein distribution
in the developing monkey brain is highly restricted to
temporal and occipital lobe regions. Consequently, MET
immunoreactivity is detected only in the anterior commis-
sure, the sublenticular internal capsule and the posterior
corpus callosum, which carry axons between these select
cortical areas. Thus, given the collective data that Met can
influence synaptic development, we suggest that MET may
influence the wiring of select circuits in the primate brain,
particularly those that are relevant to the processing of
complex visual stimuli, including faces (Pinsk et al. 2009;
Pinsk et al. 2005; Moeller et al. 2008; Tsao and Livingstone
2008). This can be tested empirically, similar to recent
correlations between CNTNAP2 and frontal connectivity in
humans (Scott-Van Zeeland et al. 2010).
The developmental profile of MET expression provides
insight into how alterations in MET expression during
development may contribute to some of the endopheno-
types observed in ASD. The temporal pattern of MET
expression in both rodents and primates is consistent with
the proposed role of this protein in influencing the wiring of
forebrain circuits, most likely through combined effects on
axon and dendritic growth and synapse formation and
maturation. The spatial expression patterns identify the
specific circuits that are likely to be affected by alterations
in MET expression. Most intriguingly with respect to ASD,
it appears that cortical circuits important for processing
socially relevant cues (e.g., auditory and visual circuits in
the primate), would be most impacted by disruptions in
MET signaling.
Concluding remarks
Functional data in children and adults with ASD suggest
that it is a neurodevelopmental disorder that has its roots in
the disruption of developing connectivity (Geschwind and
Levitt 2007; Minshew et al. 1997). It therefore should not
come as a surprise that many of the most compelling
candidate genes for rare/syndromic and idiopathic forms of
ASD are involved in aspects of brain wiring and synaptic
function (Bourgeron 2009). However, there are practical
limitations to providing definitive evidence beyond corre-
lational human and animal studies that a particular gene is a
risk factor for ASD. Excitement regarding claims of
developmental neurobiological relevance or function at the
forming synapse is muted by the fact that there are
thousands of pre- and postsynaptic gene products (Ryan
and Grant 2009), and a large part of the genome is
expressed at some time in primate brain development
(Johnson et al. 2009). Thus, there is a strong likelihood
that any statistically identified ASD candidate gene can
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reasonably be proposed to have biological relevance to the
disorder. The challenge, therefore, is to gather convergent
lines of evidence that show consistency in clinical, genetic,
and neurobiological phenomena that relate to ASD risk.
Here, recent published and preliminary findings were
summarized that, as we suggest, make a strong case for a
new player that contributes to ASD vulnerability at the
developing synapse—the MET receptor tyrosine kinase.
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